Learning Hub
Explore resources to help you understand and manage psoriatic arthritis.
Search
151 results found with an empty search
- Ethics, legal, exploitation | iPROLEPSIS
Ethics, legal and exploitation team Dr. Ioannis Drivas DIADIKASIA BUSINESS CONSULTING SYMVOULOI EPICHEIRISEON AE (DBC) Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Project Manager What are your main activities in the project? As Project Manager, I coordinate all iPROLEPSIS-related activities assigned to DBC. What is your motivation? My motivation stems from a strong commitment to upholding ethical and legal standards in research while maximizing the impact and real-world use of the iPROLEPSIS results. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication
- iPROLEPSIS presented at PhD DEI 2023 | iPROLEPSIS
< BACK iPROLEPSIS presented at PhD DEI 2023 Nov 13, 2023 Highlights from PhD DEI 2023 Organised by the Universidade de Lisboa (the Instituto Superior Técnico), the PhD DEI 2023 event on 10 November 2023 served as a platform for introducing new PhD students to the Department of Engineering and Informatics (DEI). The event fostered an environment of knowledge-sharing and collaboration among students from the Doctoral Program in Computer Science and Engineering and the Doctoral Program in Digital Media. One of the standout presentations at PhD DEI 2023 was the poster presentation on the iPROLEPSIS Exergames. This presentation, delivered by Bárbara Ramalho, a PhD student from the FMH-ULisboa team, highlighted the general concepts and objectives of the iPROLEPSIS project. The iPROLEPSIS Exergames were developed through a co-design process, emphasizing collaborative and innovative approaches to game design aimed at promoting physical activity and health. Read more: We now know the audience's favorite posters from PhD DEI 2023! - Departamento de Engenharia Informática (DEI) ( ulisboa.pt ) 1/1 PREVIOUS NEXT
- Networking | iPROLEPSIS
Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health. INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.
- Learning Hub | iPROLEPSIS
Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts Key Facts Quizzes about Psoriatic Arthritis Take a Quiz Search about Psoriatic Arthritis Search Psoriatic Arthritis Handbook Handbook News Feed about Psoriatic Arthritis News Feed
- iPROLEPSIS Newsletter No. 9 | iPROLEPSIS
< BACK iPROLEPSIS Newsletter No. 9 Jul 2, 2025 Latest News from iPROLEPSIS Welcome to the ninth edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter_Issue No. 9_July 2025 .pdf Download PDF • 3.75MB iPROLEPSIS_newsletter cover.png iPROLEPSIS_newsletter cover.png 1/1 PREVIOUS NEXT
- How will psoriatic arthritis affect me? Work | iPROLEPSIS
Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Work See related Handbook section PREVIOUS NEXT
- Co-Designing Mobile Serious Games to Support Patients With Psoriatic Arthritis and Chronic Pain: Mixed Methods Study | iPROLEPSIS
< BACK Co-Designing Mobile Serious Games to Support Patients With Psoriatic Arthritis and Chronic Pain: Mixed Methods Study Feb 3, 2026 New peer-reviewed publication from iPROLEPSIS A new paper "Co-Designing Mobile Serious Games to Support Patients With Psoriatic Arthritis and Chronic Pain: Mixed Methods Study" from the iPROLEPSIS project was published in JMIR Serious Games (Vol. 14, 2026). The study reports on the co-design and usability evaluation of NoPain Games, mobile serious games developed to support chronic pain management in people living with psoriatic arthritis. Using a mixed-methods approach, the research combined a multidisciplinary co-creation session with clinical, research, and technical experts and a usability feedback session with patients with psoriatic arthritis. The findings highlight the value of co-design methodologies for developing accessible and patient-centred digital health interventions. 🔗 Publication: https://games.jmir.org/2026/1/e75072 iPROLEPSIS_publication_JMIR Serious Games.png iPROLEPSIS_publication_JMIR Serious Games.png 1/1 PREVIOUS NEXT
- Highlights from IEEE MELECON 2024 | iPROLEPSIS
< BACK Highlights from IEEE MELECON 2024 Jun 28, 2024 Highlights from IEEE MELECON 2024 The iPROLEPSIS breathing games have been presented and well received by the audience at the IEEE MELECON 2024 scientific conference. The conference was held in Porto, Portugal on 25-27 June, 2024. IEEE MELECON 2024 is a major international forum presenting design methodologies, techniques, and experimental results in emerging electro-technologies. It is one of the flagship conferences of the IEEE Region 8 (the largest region of IEEE including Europe, Africa, and Middle East). It is expected to bring together researchers and practitioners from different fields of Electrical Engineering. Read more: IEEE MELECON 2024 – IEEE MELECON 2024 ( ieee-melecon.org ) . 1/5 PREVIOUS NEXT
- How is psoriatic arthritis treated? Self-care and lifestyle | iPROLEPSIS
Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis treated? Self-care and lifestyle See related Handbook section PREVIOUS NEXT
- Innovating Psoriatic Arthritis Care with iPROLEPSIS | iPROLEPSIS
< BACK Innovating Psoriatic Arthritis Care with iPROLEPSIS Oct 29, 2024 Insights Shared in Psoriasis Magazine: An Interview with Psoriasis Patienten Nederland We are pleased to share that we were interviewed by Psoriasis Patients Netherlands ( https://psoriasispatientennederland.nl/ ) and featured in their Psoriasis Magazine . This dedicated volunteer organisation advocates for over 300,000 people in the Netherlands affected by psoriasis and psoriatic arthritis. Supporting Patients Psoriasis Patients Netherlands provides clear, unbiased information on managing chronic conditions and serves as a vital link between patients, healthcare providers, and the latest research. Their focus is on patient support, offering resources like their magazine, social media, and direct support channels, creating an invaluable network for those navigating these challenging conditions. Digital Health Innovation The Erasmus MC in Rotterdam, through the iPROLEPSIS Consortium , is developing an app to help patients with psoriatic arthritis monitor their condition using digital health tools. Over 600 patients across four countries will use the app and smartwatches to track their heart rate, activity, and symptoms daily, along with periodic video analyses and healthcare visits. Key Research Areas The key research areas include exploring the roles of genetics, gut microbiome, and lifestyle factors. Collaborations with organizations like HPOS will soon allow individuals with psoriasis to contribute their data, supporting predictive models for earlier diagnosis. Empowering Patients Through Partnership The Erasmus MC’s iPROLEPSIS study is not just about technological development; it is driven by the stories of patient partners like Elaine and Wendy. Their lived experience with psoriatic arthritis informs our work, ensuring that the tools we develop support their needs and enhance their well-being. With patient partners at the core of the iPROLEPSIS initiative, we are creating a future where digital tools empower psoriatic arthritis patients. 1/1 PREVIOUS NEXT
- What is psoriatic arthritis? | iPROLEPSIS
Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search What is psoriatic arthritis? See related Handbook section PREVIOUS NEXT
- ChatGPT in Nutrition: Trends, Challenges and Future Directions | iPROLEPSIS
< BACK ChatGPT in Nutrition: Trends, Challenges and Future Directions Jun 27, 2024 Exploring the Role of AI in Shaping the Future of Personalised Nutrition Introducing our latest iPROLEPSIS publication, "ChatGPT in Nutrition: Trends, Challenges, and Future Directions" , presented at PETRA 2024. This study explores the evolving role of AI in personalized nutrition. Abstract: A healthy and balanced diet is of paramount importance to the physical and psychological well-being of an individual, since unhealthy dietary choices have been linked with the occurrence of non-communicable diseases. Recent technological advances has led to the development of large language models, such as ChatGPT that has been widely adopted as a convenient tool for creating meal plans and obtaining nutritional information. This work aims to provide a thorough review of the scientific work performed so far regarding the use of ChatGPT in the field of nutrition. In this survey, the advantages and limitations of ChatGPT in different aspects of nutrition are pinpointed, while the challenges from the use of ChatGPT in nutrition are identified and discussed. Future research directions are also proposed to assist researchers towards the development of more effective nutrition recommendation systems. Read the full publication: https://zenodo.org/records/13142880 ChatGPT in Nutrition .pdf Download PDF • 620KB 1/1 PREVIOUS NEXT
